A fixed-dose combination of abacavir/lamivudine as a nucleoside basis for first-line antiretroviral therapy regimens


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review shows the comparative efficacy, safety, and tolerability of an abacavir/lamivudine combination in antiretroviral therapy regimens. Trials have indicated its virological efficiency equal to that of a zidovudine/lamivudine combination, including also that in patients with a high baseline viral load. At the same time, the patients taking abacavir were less frequently observed to have anemia, nausea, vomiting, which were common in those receiving zidovudine. The trials comparing the regimens using the fixed-dose combinations of abacavir/lamivudine and tenofovir/emtricitabine have demonstrated that the virological efficiency of abacavir-containing regimens used in patients with a high baseline viral load may be decreased. However, there are papers that refute this assertion. Abacavir hypersensitivity is a major serious adverse event. HLA В*5701 testing and abacavir use only in the presence of negative test results allow the manifestations of hypersensitivity to be prevented. Abacavir should be used with caution due to the discrepant data regarding the association between its intake and the higher incidence of myocardial infarction and cardiovascular diseases in patients at other risks for diseases of the heart and vessels. Abacavir/lamivudine regimens did not cause any significant metabolic disturbances or have a negative impact on lipid metabolism, renal function, and bone mineral density.

Full Text

Restricted Access

About the authors

V. V Konnov

Federal Research and Guidance Center for AIDS Prevention and Control, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare

Email: vlad_konnov@mail.ru

N. V Kozyreva

Federal Research and Guidance Center for AIDS Prevention and Control, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare

Email: nad-kozyrina@yandex.ru

V. G Kanestri

Federal Research and Guidance Center for AIDS Prevention and Control, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare

Email: kanestri@yandex.ru

R. S Narsia

Federal Research and Guidance Center for AIDS Prevention and Control, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare

Email: narsia@hivrussia.net

O. G Yurin

Federal Research and Guidance Center for AIDS Prevention and Control, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare

Email: oleg_gerald@mail.ru

References

  1. Fast track: Ending the AIDS epidemic by 2030. UNAIDS, 2014. http://www.unaids.org/en/resources/documents/2014/ fast_track
  2. Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Канестри В.Г., Афонина Л.Ю. и др. Протоколы диспансерного наблюдения и лечения больных ВИЧ -инфекцией. Национальное научное общество инфекционистов. Эпидемиол. инфекц. болезни. Актуал. вопр. 2014; 6(приложение). 48 с.
  3. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. DHSS, 2014. http://www.aidsinfo.nih.gov/guidelines
  4. Gunthard H.F., Aberg J.A., Eron J.J., Hoy J.F., Telenti A., Benson C.A. et al. Antiretroviral treatment of adult HIV infection 2014 recommendations of the International AIDS Society-USA Panel. JAMA 2014; 312(4): 410-425.
  5. Сводное руководство по использованию антиретровирусных препаратов для лечения и профилактики ВИЧ -инфекции. ВОЗ, 2013. http://www.who.int/ru/
  6. Guidelines European AIDS Cinical Society. Version 7.1. November 2014. http://www.europeanaidsclinicalsociety.org.
  7. Rockstroh J., Hoffman С. HIV 2012/2013. http://www.hivbook.files.wordpress.com/2011/10/hivbook-2012.pdf
  8. Willing J.H., Abroms S., Westfall A.O., Routman J., Adusumilli S., Varshney M. et al. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS 2008; 22(15): 1951-1960.
  9. Афонина Л.Ю., Воронин Е.В., Фомин Ю.А., Козырина Н.В., Юрин О.Г., Покровский В.В. и др. Применение антиретровирусных препаратов в комплексе мер, направленных на профилактику передачи ВИЧ от матери ребенку. Клинический протокол. Эпидемиол. инфекц. болезни. Актуал. вопр. 2013; 1(приложение). 16 с.
  10. DeJesus E., Herrera G., Teofilo E., Gerstoft J., Hernandez J., Bonny T. For the CNA30024 study team abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin. Infec. Dis. 2004; 39: 1038-1046.
  11. Smith K.Y., Patel P., Fine D., Bellos N., Sloan L., Lackey P., Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment AIDS 2009; 23(12): 1547-1556.
  12. Sax P., Tierney C., Collier A., Fischl M., Godfrey C., Jahed N. et al. ACTG 5202: shorter time to virologic failure (VF) with abacavir/lamivudine (ABC/3TC) than tenofovir / emtricitabine (TDF/FTC) as part of combination therapy in treatment-naïve subjects with screening HIV RNA > 100,000 c/m. In: Program and abstracts of the XVII International AIDS conference. Mexico, 2008; THAB0303.
  13. Sax P., Tierney C., Collier A.C., Fischl M.A., Mollan K., Peeples L. et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N. Engl. J. Med. 2009; 361(23): 2230-2240. http://www.ncbi.nlm.nih.gov/pubmed/19952143
  14. Daar E., Tierney C., Fischl M., Collier A.C., Mollan K., Budhathoki C. et al. ACTG 5202: Final results of ABC/3TC or TDF/FTC with either EFV or ATV/rin treatment-naive H IV-infected. Program and abstracts of the XVII Conference on Retroviruses and Opportunistic Infections. San Francisco, 2010; 59 LB.
  15. Stellbrink H.J., Moyle G., Orkin C., Compston J., Arribas J.R., Domingo P. et al. Assessment of safety and efficacy of abacavir/lamivudine and tenofovir/emtricitabine in treatment-naive HIV-1 infected subjects. Assert: 48-week result. 12th European AIDS Conference. Germany, 2009; PS10/1.
  16. Moyle G., Stellbrink H.J., Compston J., Orkin C., Arribas J.R., Domingo P. et al. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviralnaive, HIV-1-infected adults: ASSERT study. Antiviral Therapy 2013; 18: 905-913.
  17. Martinez E., Arranz J.A., Podzamczer D., Loncâ M., Sanz J., Barragân P. et al. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1 infected patients with virological suppression (BICOMBO). J. Acquir. Immune Defic. Syndr. 2009; 51(3): 290-297.
  18. Raffi F., Jaeger H., Quiros-Roldan E., Albrecht H., Belonosova E., Gatell J.M. et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, doubleblind, non-inferiority trial. The Lancet Infectious Diseases 2013; 13(11): 927-935.
  19. Walmsley S.L., Antela A., Clumeck N., Duiculescu D., Eberhard A., Gutiérrez F. et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N. Engl. J. Med. 2013; 369(19): 1807-1818.
  20. Molina J-M., Clotet B., van Lunzen J., Lazzarin A., Cavassini M., Henry K. et al. Once-daily dolutegravir is superior to oncedaily darunavir/ritonavir in treatment-naïve HIV-1-infected individuals: 96-week results from FLAMINGO (ING114915). J. Int. AIDS Soc. 2014; 17(3): abstract 0153.
  21. Бартлетт Д., Галлант Д., Фам П. Клинические аспекты ВИЧ-инфекции. М.: Р. Валент, 2012. 528 с.
  22. Nolan D., Gaudieri S., Mallal S. Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity. J. HIV Ther. 2003; 8(2): 36-41.
  23. Цыганова Г.М., Буравцова Е.В., Покровский В.В. Опыт использования набора реагентов «АмплиСенс® Геноскрин HLA B*5701-FL» в практической лаборатории. Сборник трудов VIII Всероссийской научно-практической конференции «Молекулярная диагностика 2014». М., 2014; 1: 41.
  24. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22(14): 17-24.
  25. Trevillyan J.M., Cheng A.C. Hoy J. Abacavir exposure and cardiovascular risk factors in HIV-positive patients with coronary heart disease: a retrospective case-control study. Sex Health. 2013; 10(2): 97-101.
  26. Martin A., Bloch M., Amin J., Baker D., Cooper D.A., Emery S. et al. Simplification of antiretroviral therapy with Tenofovir-Emtricitabine or Abacavir-Lamivudine: a randomized, 96-week trial (STEAL). Clin. Infect. Dis. 2009; 49: 1591-1601.
  27. McComsey G., Kitch D., Daar E., Tierney C., Jahed N.C., Melbourne K., et al. Bone and limb fat outcomes of ACTG A5224s, a substudy of ACTG A5202: a prospective, randomized, partially blinded phase III trial of ABC/3TC or TDF/FTC with EFV or ATV/r for initial treatment of HIV-1 infection. Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, 2010; 106 LB.
  28. Palella F.J.Jr., Gange S.J., Benning L., Jacobson L., Kaplan R.C., Landay A.L. et al. Inflammatory biomarkers and abacavir use in the women's interagency hiv study and the multicenter aids cohort study. AIDS 2010; 24(11): 1657-1665.
  29. Markowicz S., Delforge M., Necsoi C., De Wit S. Cardiovascular risk evaluation of HIV-positive patients in a case-control study: comparison of the D:A:D and framingham equations. J. Int. AIDS Soc. 2014; 17(4, Suppl 3): 19515.
  30. Xiao D., Andraca-Carrera E., Cooper C., Miele P., Kornegay C., Soukup M., Marcus C. No association of abacavir use with myocardial infarction. findings of an fda meta-analysis. J. Acquir. Immune Defic. Syndr. 2012; 61(4): 441-447.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies